Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways

Tine Cuppens, Matthieu Moisse, Jeroen Depreeuw, Daniela Annibali, Eva Colas, Antonio Gil-Moreno, Jutta Huvila, Olli Carpén, Michal Zikán, Xavier Matias-Guiu, Philippe Moerman, Sabrina Croce, Diether Lambrechts, Frédéric Amant

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

© 2017 UICC Uterine leiomyosarcomas (uLMS) are rare, aggressive malignancies for which limited treatment options are available. To gain novel molecular insights into uLMS and identify potential novel therapeutic targets, we characterized 84 uLMS samples for genome-wide somatic copy number alterations, mutations, gene fusions and gene expression and performed a data integration analysis. We found that alterations affecting TP53, RB1, PTEN, MED12, YWHAE and VIPR2 were present in the majority of uLMS. Pathway analyses additionally revealed that the PI3K/AKT/mTOR, estrogen-mediated S-phase entry and DNA damage response signaling pathways, for which inhibitors have already been developed and approved, frequently harbored genetic changes. Furthermore, a significant proportion of uLMS was characterized by amplifications and overexpression of known oncogenes (CCNE1, TDO2), as well as deletions and reduced expression of tumor suppressor genes (PTEN, PRDM16). Overall, it emerged that the most frequently affected gene in our uLMS samples was VIPR2 (96%). Interestingly, VIPR2 deletion also correlated with unfavorable survival in uLMS patients (multivariate analysis; HR = 4.5, CI = 1.4–14.3, p = 1.2E-02), while VIPR2 protein expression was reduced in uLMS vs. normal myometrium. Moreover, stimulation of VIPR2 with its natural agonist VIP decreased SK-UT-1 uLMS cell proliferation in a dose-dependent manner. These data suggest that VIPR2, which is a negative regulator of smooth muscle cell proliferation, might be a novel tumor suppressor gene in uLMS. Our work further highlights the importance of integrative molecular analyses, through which we were able to uncover the genes and pathways most frequently affected by somatic alterations in uLMS.
Original languageEnglish
Pages (from-to)1230-1243
JournalInternational Journal of Cancer
Volume142
Issue number6
DOIs
Publication statusPublished - 15 Mar 2018

Keywords

  • RNA sequencing
  • copy number alteration
  • data integration
  • molecular profiling
  • uterine leiomyosarcoma

Fingerprint Dive into the research topics of 'Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways'. Together they form a unique fingerprint.

  • Cite this

    Cuppens, T., Moisse, M., Depreeuw, J., Annibali, D., Colas, E., Gil-Moreno, A., Huvila, J., Carpén, O., Zikán, M., Matias-Guiu, X., Moerman, P., Croce, S., Lambrechts, D., & Amant, F. (2018). Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 142(6), 1230-1243. https://doi.org/10.1002/ijc.31129